<SEC-DOCUMENT>0001140361-23-013852.txt : 20230327
<SEC-HEADER>0001140361-23-013852.hdr.sgml : 20230327
<ACCEPTANCE-DATETIME>20230327060129
ACCESSION NUMBER:		0001140361-23-013852
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230327
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230327
DATE AS OF CHANGE:		20230327

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IONIS PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000874015
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				330336973
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19125
		FILM NUMBER:		23761343

	BUSINESS ADDRESS:	
		STREET 1:		2855 GAZELLE COURT
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92010
		BUSINESS PHONE:		7609319200

	MAIL ADDRESS:	
		STREET 1:		2855 GAZELLE COURT
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ISIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>brhc10050366_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:ions="http://ionispharma.com/20230327" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: broadridge
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_68ed63d7b310478980a31a03b7ce7d6e" contextRef="c20230327to20230327" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_d5a3a074eaf349c9b3adbb87960d9372" contextRef="c20230327to20230327">0000874015</ix:nonNumeric><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_45e9c423bc0248aeb99ee7c72012cfd3" contextRef="c20230327to20230327">NASDAQ</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="ions-20230327.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20230327to20230327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-27</xbrli:startDate><xbrli:endDate>2023-03-27</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
  <div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">Washington, D.C.&#160; 20549</div>

    <div>&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_d7eb6e1786ea481eb2c8a1965e50dc71" contextRef="c20230327to20230327">8-K</ix:nonNumeric></div>

    <div>&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">PURSUANT TO SECTION 13 OR 15(d) OF THE</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SECURITIES EXCHANGE ACT OF 1934</div>

    <div>&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Date of report (Date of earliest event reported):&#160; <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_582beab6c5674070af5c0635e651330f" contextRef="c20230327to20230327" format="ixt:date-monthname-day-year-en">March 27, 2023</ix:nonNumeric></div>

    <div>&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_2c1bc374aee2490b95176d17ade28357" contextRef="c20230327to20230327">IONIS PHARMACEUTICALS, INC.</ix:nonNumeric><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Exact Name of Registrant as Specified in Charter)</div>

    <div>&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_cd718218e37d4114b6c1cd3b6f0e0c4d" contextRef="c20230327to20230327" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(State or Other Jurisdiction of Incorporation)</div>

    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_63f63d78cc2c484098f3785336c0169d" contextRef="c20230327to20230327">000-19125</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_85b5303845d541ddb1378e8f65dabda9" contextRef="c20230327to20230327">33-0336973</ix:nonNumeric><br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Commission File No.)</div>
          </td>

    <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(IRS Employer Identification No.)</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_3272b5f3b4b7439f957c24bfd1617528" contextRef="c20230327to20230327">2855 Gazelle Court</ix:nonNumeric><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_2ecb7fbe208e4ac88d5f41f4d84b9e90" contextRef="c20230327to20230327">Carlsbad</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_7ead565c2fd0422e89fc8c4ab7d25f61" contextRef="c20230327to20230327">CA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_20cc92034ad9432aaaa4ab4a84309144" contextRef="c20230327to20230327">92010</ix:nonNumeric></div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Address of Principal Executive Offices and Zip Code)</div>

    <div>&#160;</div>

    <div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Registrant&#8217;s telephone number, including area code: <span style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_ec45ef7243944b6d9da43fd6d42b5005" contextRef="c20230327to20230327">760</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_2f52b4663dc14ffaaa60ab709b428065" contextRef="c20230327to20230327">931-9200</ix:nonNumeric></span></div>

      <div><br />
      </div>

    </div>

    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

    <div style="text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18.7pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_ce89d01252ee4167be4975a608a9111d" contextRef="c20230327to20230327" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
          </td>

    <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
          </td>

  </tr>


</table>
    <div style="text-align: left; text-indent: -36pt; margin-left: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18.7pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_8304d0b8548c48598a0dacb290af9ff4" contextRef="c20230327to20230327" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
          </td>

    <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
          </td>

  </tr>


</table>
    <div style="text-align: left; text-indent: -36pt; margin-left: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18.7pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_14fb86846e234ff9af9d30a85e1a5863" contextRef="c20230327to20230327" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
          </td>

    <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
          </td>

  </tr>


</table>
    <div style="text-align: left; text-indent: -36pt; margin-left: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18.7pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_6c878874b1054fa68d666404e4172419" contextRef="c20230327to20230327" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
          </td>

    <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 31.1%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Title of each class</div>
          </td>

    <td style="width: 4.7%; vertical-align: top;">&#160;</td>

    <td style="width: 17.22%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Trading symbol</div>
          </td>

    <td style="width: 4.57%; vertical-align: top;">&#160;</td>

    <td style="width: 42.41%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Name of each exchange on which registered</div>
          </td>

  </tr>

  <tr>

    <td style="width: 31.1%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_e1f13c8d43bf4d6db1a5034c9ff8314a" contextRef="c20230327to20230327">Common Stock, $.001 Par Value</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 4.7%; vertical-align: top;">&#160;</td>

    <td style="width: 17.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<ix:nonNumeric name="dei:TradingSymbol" id="Fact_ded4672188c945ecaf24d91a11e5f559" contextRef="c20230327to20230327">IONS</ix:nonNumeric>&#8221;</div>
          </td>

    <td style="width: 4.57%; vertical-align: top;">&#160;</td>

    <td style="width: 42.41%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="-sec-ix-hidden:Fact_45e9c423bc0248aeb99ee7c72012cfd3">The Nasdaq Stock Market, LLC</span><br />
            </div>
          </td>

  </tr>


</table>
    <div> <br />
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or
      Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).</div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
    </div>

    <div style="text-align: right;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company</span>&#160; <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_3f9115d6a898478e86e77e917aa29093" contextRef="c20230327to20230327" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>

    <div>&#160;</div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
      financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160; &#9744;</div>

    <div>
<div>&#160;
      </div>
<hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

    </div>

    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
              <div style="text-align: justify;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 8.01</span></div>
            </td>

    <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Other Events.</span></div>
            </td>

  </tr>


</table>
    </div>

    <div>&#160;</div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">On March 27, 2023, Ionis Pharmaceuticals, Inc. issued a press release announcing positive topline results from the 66-week analysis of the Phase 3 NEURO-TTRansform study
      of eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).</div>

    <div>&#160;</div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">A copy of this press release is attached as Exhibit 99.1 to this Current Report and incorporated herein by reference.</div>

    <div>&#160;</div>

    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
              <div style="text-align: justify;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01.</span></div>
            </td>

    <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Financial Statements and Exhibits.</span></div>
            </td>

  </tr>


</table>
    </div>

    <div>&#160;</div>

    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 18pt;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">(d)</div>
            </td>

    <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Exhibits.</div>
            </td>

  </tr>


</table>
    </div>

    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 15.16%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="text-decoration: underline;">Exhibit No.</span></div>
          </td>

    <td style="width: 84.84%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="text-decoration: underline;">Description</span></div>
          </td>

  </tr>

  <tr>

    <td style="width: 15.16%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><a href="brhc10050366_ex99-1.htm">99.1</a></div>
          </td>

    <td style="width: 84.84%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Press Release dated March 27, 2023.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 15.16%; vertical-align: top; text-align: center;">&#160;</td>

    <td style="width: 84.84%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 15.16%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">104</div>
          </td>

    <td style="width: 84.84%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</div>
            </div>
          </td>

  </tr>


</table>
    <div style="text-align: justify;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span><br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps; font-weight: bold;">SIGNATURE</div>

    <div>&#160;</div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf
      by the undersigned, thereunto duly authorized.</div>

    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="vertical-align: top;" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps; font-weight: bold;">Ionis Pharmaceuticals, Inc.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="vertical-align: top;" colspan="2" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Dated:&#160; March 27, 2023</div>
          </td>

    <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">By: <br />
          </td>

    <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">/s/ Patrick R. O&#8217;Neil</span></div>
          </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps; font-weight: bold;">Patrick R. O&#8217;Neil</div>
          </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Executive Vice President, Chief Legal Officer and General Counsel</div>
          </td>

  </tr>


</table>
    <div> <br />
    </div>

    <div> <br />
    </div>

    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /> </div>

  </div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>brhc10050366_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finacial Solutions inc.
         Document created using Broadridge PROfile 23.2.1.5134
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div> <br>
  </div>
  <div><img src="image00001.jpg">
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Ionis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z005fbf7ebd94485e8dafba841791e5ac">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8722;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Eplontersen met co-primary endpoints demonstrating sustained reduction in TTR and benefits in neuropathy and quality of life through 66 weeks</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zba9ef161a433464f817e8f27230bea96">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8722;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">35 and 66-week data to be presented at the American Academy of Neurology (AAN) Annual Meeting in April</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CARLSBAD, Calif., March 27, 2023</font> &#8211; <u><font style="font-style: normal;">Ionis Pharmaceuticals, Inc</font></u>. (Nasdaq: IONS) today announced positive topline results from the 66-week analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca&#8217;s eplontersen in patients with
      hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), a debilitating and potentially fatal disease that leads to peripheral nerve damage and motor disability.</div>
    <div><br>
    </div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">At 66 weeks, patients treated with eplontersen continued to demonstrate a statistically significant and clinically meaningful change from baseline
      versus an external placebo group on the co-primary endpoints of modified Neuropathy Impairment Score +7 (mNIS+7), a measure of neuropathic disease progression, and Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN). The study
      also met its third co- primary endpoint demonstrating a statistically significant reduction in serum TTR concentration versus an external placebo group. TTR reductions were consistent with those reported at week 35. Eplontersen continued to
      demonstrate a safety and tolerability profile consistent with that observed at 35 weeks.</div>
    <div><br>
    </div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#8220;The positive results from the 66-week analysis of the Phase 3 NEURO-TTRansform trial
        show that eplontersen provided consistent and sustained transthyretin protein reduction and that a substantial number of patients improved in measures of both neuropathy progression and quality of life,&#8221; said Sami Khella, M.D., chief, department of
        neurology, Penn Presbyterian Medical Center and professor of clinical neurology, University of Pennsylvania School of Medicine. &#8220;This builds on the favorable 35-week results</font>, which first demonstrated <font style="font-family: 'Times New Roman'; font-size: 10pt;">eplontersen&#8217;s potential to significantly improve outcomes in this underserved population.&#8221;</font></div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#8220;The</font>se latest<font style="font-family: 'Times New Roman'; font-size: 10pt;"> results from our
        NEURO-TTRansform study represent an important step towards delivering a potential new therapy for ATTRv-PN patients living with this debilitating and fatal disease. </font>We are encouraged by the sustained benefit demonstrated by eplontersen and
      what a self-administered treatment could mean for patients and families affected by ATTRv-PN,&#8221; said Eugene Schneider, M.D., executive vice president and chief clinical development officer for Ionis. &#8220;Together, with our partner AstraZeneca, we look
      forward to sharing detailed results from this study at the upcoming American Academy of Neurology Annual Meeting.&#8221;</div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8220;These results further underscore eplontersen&#8217;s potential to be a best-in-class treatment across all forms of transthyretin-mediated amyloidosis,
      including polyneuropathy and cardiomyopathy which can lead to heart failure,&#8221; said Mene Pangalos, executive vice president, BioPharmaceuticals R&amp;D, AstraZeneca. &#8220;With limited treatment options currently available, there is an urgent unmet medical
      need for new therapies and earlier, accurate diagnosis across the different types of this systemic, progressive and fatal condition.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Data from both the 35 and 66-week analyses will be presented as an Emerging Science presentation at the American Academy of Neurology (AAN) Annual
      Meeting in April. The initial results from the 35-week analysis were presented at the International Symposium on Amyloidosis meeting in <u>September 2022</u>.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">As part of a global <u>development and commercialization</u> agreement, Ionis and AstraZeneca are seeking regulatory approval for eplontersen for the treatment of ATTRv-PN
      in the U.S. and plan to seek regulatory approval in Europe and other parts of the world. Earlier this month, the U.S. Food and Drug Administration accepted a <u>New Drug Application</u> for eplontersen for the treatment of ATTRv-PN with a PDUFA
      action date of Dec. 22, 2023. Eplontersen was <u>granted Orphan Drug Designation</u> in the U.S.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Eplontersen is currently being evaluated in the Phase 3 CARDIO-TTRansform study for transthyretin amyloid cardiomyopathy (ATTR-CM), a systemic, progressive and fatal
      condition that typically leads to progressive heart failure and often death within three to five years from disease onset.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About the NEURO-TTRansform Study</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">NEURO-TTRansform is a global, open-label, randomized trial evaluating the efficacy and safety of eplontersen in patients with ATTRv-PN. The trial enrolled adult patients
      with ATTRv-PN Stage 1 or Stage 2 and up to week 66 eplontersen is being compared to the external placebo group from the NEURO-TTR registrational trial for inotersen that Ionis completed in 2017. The final analysis comparing eplontersen to external
      placebo was completed at week 66 and all patients will be followed on treatment until week 85, when they will have the option to transition into an open-label extension study. For more information on the NEURO-TTRansform study, please visit: <u>https://clinicaltrials.gov/ct2/show/NCT04136184</u></div>
    <div style="text-align: left;"><font style="font-family: 'Times New Roman'; font-size: 10pt;"> </font><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN)</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) is caused by the accumulation of misfolded mutated TTR protein in the peripheral nerves. Patients with
      ATTRv-PN experience ongoing debilitating nerve damage throughout their body resulting in the progressive loss of motor functions, such as walking. These patients also accumulate TTR in other major organs, which progressively compromises their
      function. The damage from misfolded TTR protein accumulation leads to disability within five years of diagnosis and is generally fatal within a decade.</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Eplontersen</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Eplontersen is an investigational <font style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">LI</font>gand-<font style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">C</font>onjugated <font style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">A</font>ntisense (LICA) medicine designed to inhibit the production of TTR protein. Eplontersen is
      being developed as a monthly self-administered subcutaneous injection to treat all types of ATTR. ATTR amyloidosis is a systemic, progressive and fatal disease in which patients experience multiple overlapping clinical manifestations caused by the
      inappropriate formation and aggregation of TTR amyloid deposits in various tissues and organs, including peripheral nerves, heart, intestinal tract, eyes, kidneys, central nervous system, thyroid and bone marrow. The progressive accumulation of TTR
      amyloid deposits in these tissues and organs leads to organ failure and eventually death.</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Ionis Pharmaceuticals, Inc.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis
      currently has three marketed medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our
      vision to become the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">To learn more about Ionis visit <u>www.ionispharma.com</u> and follow us on Twitter @ionispharma.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Ionis' Forward-looking Statements</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of Ionis' technologies, eplontersen and other
      products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain
      risks and uncertainties, including but not limited to, those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe
      and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to
      differ materially from those expressed or implied by such forward-looking statements.</div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis.
      As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2022, which is on
      file with the Securities and Exchange Commission. Copies of this and other documents are available from the Company.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers to Ionis Pharmaceuticals and its subsidiaries.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Ionis Pharmaceuticals<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is a trademark of Ionis Pharmaceuticals, Inc.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Ionis Investor Contact:</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">D. Wade Walke, Ph.D.</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><u>info@ionisph.com</u></div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">760-603-2331</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Ionis Media Contact:</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Sophia Patel</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><u>ionis_ca@ionisph.com</u></div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">760-603-4679</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ions-20230327.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.1.5138 Broadridge-->
<xs:schema targetNamespace="http://ionispharma.com/20230327" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:ions="http://ionispharma.com/20230327" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="ions-20230327_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ions-20230327_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://ionispharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ions-20230327_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.1.5138 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ions-20230327_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.1.5138 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://ionispharma.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="ions-20230327.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://ionispharma.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !1 +X# 2(  A$! Q$!_\0
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MF:BFZ"9(!GNC?/AA[@UYSXP\.7OA77KC3-07YHSF.0#Y94/1A_GK7K7[+_\
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M;S,@+C?P,<@>_'71V%I&'"6\2AT,;84?,I).#[99C^)J%]'TY[N*Z:RMS<1
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$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140601342632832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 27, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 27,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-19125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IONIS PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000874015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0336973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2855 Gazelle Court<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carlsbad<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">931-9200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.001 Par Value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IONS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>brhc10050366_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ions-20230327.xsd" xlink:type="simple"/>
    <context id="c20230327to20230327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <startDate>2023-03-27</startDate>
            <endDate>2023-03-27</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20230327to20230327"
      id="Fact_68ed63d7b310478980a31a03b7ce7d6e">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20230327to20230327"
      id="Fact_d5a3a074eaf349c9b3adbb87960d9372">0000874015</dei:EntityCentralIndexKey>
    <dei:SecurityExchangeName
      contextRef="c20230327to20230327"
      id="Fact_45e9c423bc0248aeb99ee7c72012cfd3">NASDAQ</dei:SecurityExchangeName>
    <dei:DocumentType
      contextRef="c20230327to20230327"
      id="Fact_d7eb6e1786ea481eb2c8a1965e50dc71">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20230327to20230327"
      id="Fact_582beab6c5674070af5c0635e651330f">2023-03-27</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20230327to20230327"
      id="Fact_2c1bc374aee2490b95176d17ade28357">IONIS PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20230327to20230327"
      id="Fact_cd718218e37d4114b6c1cd3b6f0e0c4d">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20230327to20230327"
      id="Fact_63f63d78cc2c484098f3785336c0169d">000-19125</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20230327to20230327"
      id="Fact_85b5303845d541ddb1378e8f65dabda9">33-0336973</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20230327to20230327"
      id="Fact_3272b5f3b4b7439f957c24bfd1617528">2855 Gazelle Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20230327to20230327"
      id="Fact_2ecb7fbe208e4ac88d5f41f4d84b9e90">Carlsbad</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20230327to20230327"
      id="Fact_7ead565c2fd0422e89fc8c4ab7d25f61">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20230327to20230327"
      id="Fact_20cc92034ad9432aaaa4ab4a84309144">92010</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20230327to20230327"
      id="Fact_ec45ef7243944b6d9da43fd6d42b5005">760</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20230327to20230327"
      id="Fact_2f52b4663dc14ffaaa60ab709b428065">931-9200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20230327to20230327"
      id="Fact_ce89d01252ee4167be4975a608a9111d">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20230327to20230327"
      id="Fact_8304d0b8548c48598a0dacb290af9ff4">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20230327to20230327"
      id="Fact_14fb86846e234ff9af9d30a85e1a5863">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20230327to20230327"
      id="Fact_6c878874b1054fa68d666404e4172419">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20230327to20230327"
      id="Fact_e1f13c8d43bf4d6db1a5034c9ff8314a">Common Stock, $.001 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20230327to20230327"
      id="Fact_ded4672188c945ecaf24d91a11e5f559">IONS</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20230327to20230327"
      id="Fact_3f9115d6a898478e86e77e917aa29093">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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ML0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^*T(_8&YB:N*1&+9
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M8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ +C![5IE<G",0!@  G"<  !,
M             ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M"  N,'M6A+@)=E0$  "1$   &               @($,"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ +C![5I^@&_"Q @  X@P   T
M             ( !E@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  N,'M6
MEXJ[',     3 @  "P              @ %R#P  7W)E;',O+G)E;'-02P$"
M% ,4    "  N,'M6'#AEZC\!   \ @  #P              @ %;$   >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ +C![5B0>FZ*M    ^ $  !H
M         ( !QQ$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ +C![5F60>9(9 0  SP,  !,              ( !K!(  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ]A,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="brhc10050366_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionispharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName -  brhc10050366_8k.htm 11</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="brhc10050366_8k.htm">brhc10050366_8k.htm</File>
    <File>brhc10050366_ex99-1.htm</File>
    <File>ions-20230327.xsd</File>
    <File>ions-20230327_lab.xml</File>
    <File>ions-20230327_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "brhc10050366_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "brhc10050366_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ions-20230327_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ions-20230327_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ions-20230327.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 29,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ions",
   "nsuri": "http://ionispharma.com/20230327",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050366_8k.htm",
      "contextRef": "c20230327to20230327",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://ionispharma.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050366_8k.htm",
      "contextRef": "c20230327to20230327",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001140361-23-013852-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-23-013852-xbrl.zip
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MSBU(8P:B[OJD_V5P=G-V<HV.+SZAD]_[OQY?_'*"^I>?/Y]=7Y]=7M31_;Q
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M-;4])\)3[^Q#L;(USXHPH#C"S(1E0"RG_ )>A@_X<V@8=8>F'C/Y8K,SO93
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M+L6FXD!YOC!4BA.RH3Z6>E!&\#E:1*]:)&&/\Z'I3-<1ZY9?&.!X_.E^A,)
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M4_$.Q\I:7+%/_,V_15.8OREW_C]02P,$%     @ +C![5AYYQE_>!0  ]SX
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M<FAC,3 P-3 S-C9?.&LN:'1M4$L! A0#%     @ +C![5A(,>\0&$P  "$0
M !<              ( !Z1$  &)R:&,Q,# U,#,V-E]E>#DY+3$N:'1M4$L!
M A0#%     @ +C![5BDM3_=( P  0@\  !$              ( !)"4  &EO
M;G,M,C R,S S,C<N>'-D4$L! A0#%     @ +C![5NZ431E^"   =%@  !4
M             ( !FR@  &EO;G,M,C R,S S,C=?;&%B+GAM;%!+ 0(4 Q0
M   ( "XP>U8>><9?W@4  /<^   5              "  4PQ  !I;VYS+3(P
D,C,P,S(W7W!R92YX;6Q02P4&      4 !0!+ 0  73<

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
